FeesSafety
Pluang+

Gilead raises dividend for 11th year, boosts revenue guidance with strong HIV and oncology sales.

Company Fundamentals
22 Nov 2026, 16:53 WIB
The Motley Fool
View Source
Bullish
Gilead raises dividend for 11th year, boosts revenue guidance with strong HIV and oncology sales.

Gilead Sciences increased its dividend by 3.8% for the 11th consecutive year, supported by strong cash flow and a low payout ratio under 30%. The company dominates the HIV therapy market with blockbuster drugs like Biktarvy, which holds a 53% U.S. market share and patent protection through 2036. Gilead is also expanding its portfolio into oncology and liver disease treatments, with products like Trodelvy and Livdelzi showing significant sales growth. This diversification and robust pipeline position Gilead for continued revenue and dividend growth.

Gilead Sciences shares are trading at USD 166.43 on Pluang, with a slight 0.06% decrease in the past day and a dividend yield of 1.97%. The stock's market cap stands at $206.43 billion, reflecting its strong position in the health sector. These figures are current as of Nov 22, 2026 22:02 WIB.

More News (GILD)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App